Rasburicase
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Rasburicase: From Tumor Lysis Syndrome-Associated Hyperuricemia to Renal Hypouricemia
One-Sentence Summary
Rasburicase is a recombinant urate oxidase used to manage hyperuricemia associated with tumor lysis syndrome. The TxGNN model's top prediction is Renal Hypouricemia, but this candidate has zero clinical trials and zero publications supporting it, and is mechanistically inconsistent with the drug's known pharmacology — the target disease is a condition of abnormally low uric acid, while Rasburicase's known effect is to lower uric acid further.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Tumor lysis syndrome-associated hyperuricemia (from known pharmacology; no Norway license record available) |
| Predicted New Indication | Renal Hypouricemia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal structured mechanism-of-action (MOA) data is currently a Data Gap (DG002). However, based on the pharmacological description available in the evidence pack, Rasburicase is a recombinant urate oxidase (uricase) enzyme that catalyzes the oxidation of uric acid to allantoin, thereby lowering serum uric acid concentration. It is clinically used to manage hyperuricemia associated with tumor lysis syndrome in oncology patients.
The top-ranked TxGNN candidate, renal hypouricemia, is a condition characterized by abnormally low serum uric acid, typically caused by defective renal urate reabsorption (e.g., URAT1/GLUT9 transporter dysfunction). This is pharmacologically opposite in direction to Rasburicase's known uric-acid-lowering effect — there is no plausible clinical rationale for administering a uric-acid-lowering enzyme to a patient who already has pathologically low uric acid. This mechanistic contradiction is explicitly flagged in the evidence pack itself.
The high TxGNN score most likely reflects graph-embedding proximity between uric acid/purine-metabolism-related genes and pathways in the knowledge graph, rather than a genuine treatment relationship. Among the 10 candidates in this evidence pack, rank #2 (hypoxanthine-guanine phosphoribosyltransferase partial deficiency / Kelley-Seegmiller syndrome) has a more biochemically coherent rationale, since that condition causes purine-pathway-driven hyperuricemia — the direction Rasburicase is actually known to treat. However, it too currently has no supporting clinical trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Rasburicase is not marketed in Norway; no product authorization records are available (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a pure model prediction (L5) with no clinical trial or literature support, and the top-ranked candidate indication is mechanistically implausible — it reverses the direction of Rasburicase's known pharmacological effect. There is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/regulatory package insert warnings and contraindications (DG001, Blocking — currently prevents entry into S1 safety review)
- Structured MOA and DrugBank category data (DG002, High severity)
- Independent biochemical/preclinical validation of a mechanistically coherent target — rank #2 (HGPRT partial deficiency) warrants closer review before rank #1
- If pursued, a Norway regulatory pathway assessment, since the drug currently holds no local market authorization
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.